|Day Low/High||240.07 / 244.86|
|52 Wk Low/High||223.25 / 374.99|
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
I think M&A activity will pick up markedly going forward across the industry.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Charts are signalling more trouble ahead for the stock.
The biotech sector has seen a big rally, but there are still opportunities.
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Consumer spending should be more than solid given wage increases.
About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
These favorite names in the volatile sector offer the potential for high rewards.
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
Stocks closed confidently higher Tuesday.
Strong earnings from Dow components Caterpillar, McDonald's and 3M were on track to push the blue-chip index higher after a 0.23% decline on Monday.
Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."
The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
The S&P 500 and Nasdaq end at records.
These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.